

## Agilent offers AI-powered assay development solutions for biopharma research

13 April 2023 | News

Innovative AI-powered interpretation methods to meet the future needs of precision medicine



US-based Agilent Technologies Inc. has announced a strategic partnership with PathAI, a leading provider of artificial intelligence (AI)-powered research tools and services for pathology, to deliver biopharmaceutical organisations a solution that combines Agilent's assay development expertise and PathAI's algorithm development capabilities. By incorporating AI into companion diagnostics (CDx) development, the partnership enables Agilent and PathAI to build integrated solutions with assays and machine learning analysis algorithms.

Through this partnership, biopharmaceutical companies can harness an end-to-end solution for AI-powered assay development, including companion diagnostics enabled by digital pathology.

Agilent's anatomic pathology workflow expertise, large install base of tissue staining systems and reagents, combined with PathAI's proprietary algorithm development platform, and a growing network of laboratories deploying their digital pathology software solution AISight, will enable partners to realize the value of AI-driven assays from bench to bedside.

Agilent has also announced a multiyear global distribution agreement with PathAI to distribute both versions of their platform AISight and AISight DX+ along with AIM-PD-L1 NSCLC, an algorithm for PD-L1 quantification in non-small cell lung cancer (NSCLC), to anatomic pathology laboratories. Further, through this partnership, Agilent may also commercialise additional algorithms PathAI launches in the future.